Mitomycin C: a clinical update

Bradner, William T.

doi:10.1053/ctrv.2000.0202

Cited by 302 publications

(191 citation statements)

References 180 publications

(139 reference statements)

Supporting

Mentioning

183

Contrasting

Unclassified

Order By: Relevance

“…It is a highly active anticancer drug commonly used in combination with other chemotherapeutic agents for the treatment of various cancers. It is anticipated that MMC will continue to play its important role in the treatment of bladder, breast, head and neck, and non-small-cell lung cancers (Bradner, 2001). Bioreduction-mediated activation of MMC is responsible for its chemotherapeutic effects.…”

mentioning

confidence: 99%

Genetic Variation of Human Cytochrome P450 Reductase as a Potential Biomarker for Mitomycin C-Induced Cytotoxicity

Wang¹,

Han²,

He³

et al. 2006

Drug Metab Dispos

View full text Add to dashboard Cite

ABSTRACT:The importance of genetic variation in clinical response to various drugs is now well recognized. Identification of genetic biomarkers that can predict efficacy and toxicity of chemotherapeutic drugs in cancer patients holds great promise in treatment improvement and cost reduction. Mitomycin C (MMC) is a common anticancer drug used for the treatment of numerous types of tumors. Metabolismmediated activation, by either one-electron or two-electron reduction, plays a critical role in the chemotherapeutic action of MMC. NADPH-cytochrome P450 (oxido)reductase (POR) is a major enzyme responsible for MMC activation through the one-electron reductive pathway, which leads to the production of semiquinone anion radicals and subsequent DNA damage in the cells. Recently, a total of six naturally occurring human POR variants with single amino acid changes (Y181D, A287P, R457H, V492E, C569Y, and V608F) have been identified. Although the catalytic efficiency of these variants in reduction of cytochrome c was reported to be altered, their capability in activating MMC, a direct substrate of POR, has not been examined. In the present study, we demonstrated that except for the C569Y variant, MMC-induced toxicity assayed as cell viability and proliferative capability was significantly decreased in the Flp-In Chinese hamster ovary cells stably expressing all the other POR variants in comparison with the cells expressing wild-type human POR. Cells expressing the V608F and Y181D variants had a complete loss of the capability to activate MMC. Our finding suggests that these functional POR genetic variations may serve as a potential biomarker to predict the chemotherapeutic response to MMC.

show abstract

mentioning

confidence: 99%

Genetic Variation of Human Cytochrome P450 Reductase as a Potential Biomarker for Mitomycin C-Induced Cytotoxicity

Wang¹,

Han²,

He³

et al. 2006

Drug Metab Dispos

View full text Add to dashboard Cite

show abstract

“…It also suppresses cellular RNA and protein synthesis and is not cell cycle specific. Therefore, it is useful in delaying the healing process by prohibiting the replication of fibroblasts and epithelial cells and inhibiting collagen synthesis [18,19]. Other studies on mitomycin-C have shown its efficacy in preventing fibroblast proliferations and the development of fibrosis after myringotomy and trabeculectomy, thus improving the success rate of these procedures.…”

Section: Discussionmentioning

confidence: 99%

A Preliminary Study on Possible Effects of Mitomycin-C on the Collagen Content of Penis in Rat

Hosseini¹,

Mohseni²,

Alizadeh³

2016

UNOAJ

View full text Add to dashboard Cite

“…Mitomycin C is one of the drugs used in the chemotherapy of various types of cancer [3]. At first, the compound was isolated from the extract of secondary metabolites of gram-positive bacterium Streptomyces lavendulae growing on land [4].…”

Section: Introductionmentioning

confidence: 99%

Cytotoxic Effects of Ethyl Acetate Fractions From Secondary Metabolites of Streptomyces Sp. Gmy01 on Human Breast Cancer McF7 Cell Lines

Werdyani

Wijayanti

Fitria

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: This research aimed to fractionate the ethyl acetate extract from secondary metabolites of Streptomyces sp. GMY01 and to identify which fraction contains cytotoxic active compounds against human breast cancer MCF7 cell lines.Methods: Secondary metabolites were obtained from fermentation of Streptomyces Sp. GMY01 for 15 d. The supernatant containing these secondary metabolites was extracted through partition using ethyl acetate as the solvent. Fractionation of the ethyl acetate extract was conducted via column chromatography using silica gel as the solid phase while the gradient mobile phase consisted of n-hexane, ethyl acetate, and methanol. The cytotoxicity of each fraction was calculated using MTT-assay. Results:The ethyl acetate extract could be separated into 9 fractions using column chromatography. The cytotoxic effect of each fraction differed from each other. The smallest IC50 value was obtained from fraction 4. Further investigation should be conducted to discover the active anticancer compound. The active compound with cytotoxic effect was found in fraction 4 because of the highest IC50 value. Conclusion:This fraction is potential to be investigated more deeply as anticancer, especially for breast cancer.

show abstract

Mitomycin C: a clinical update

Cited by 302 publications

References 180 publications

Genetic Variation of Human Cytochrome P450 Reductase as a Potential Biomarker for Mitomycin C-Induced Cytotoxicity

Genetic Variation of Human Cytochrome P450 Reductase as a Potential Biomarker for Mitomycin C-Induced Cytotoxicity

A Preliminary Study on Possible Effects of Mitomycin-C on the Collagen Content of Penis in Rat

Cytotoxic Effects of Ethyl Acetate Fractions From Secondary Metabolites of Streptomyces Sp. Gmy01 on Human Breast Cancer McF7 Cell Lines

Contact Info

Product

Resources

About